Cagri 3R Blend (20mg) refers to a lyophilized research chemical containing a combination of Cagrilintide (an amylin analog) and Retatrutide (a triple-agonist targeting GIP, GLP-1, and glucagon receptors). In clinical and research contexts, these compounds are studied for their potential impact on weight management and blood glucose regulation.
Key Details & Composition
-
- Composition: Each vial is typically proportioned to contain a specific mix of Cagrilintide and Retatrutide (often a ratio such as 10mg/10mg or similar, totaling 20mg per vial).
- Regulatory Status: The FDA has not evaluated or approved combination blends of this nature for human or veterinary use. They are strictly sold as research chemicals for laboratory or preclinical purposes only.
Reconstitution & Dosage Overview
To use a 20mg vial for research, you must reconstitute it with bacteriostatic water (BAC) using a Peptide Reconstitution Calculator to ensure the appropriate concentration per unit of measurement.
If you are a clinical researcher, the study dosages typically follow specific stepwise increments:
-
- Starting Dose: Research usually begins at much lower volumes (e.g., 0.5 mg of Retatrutide once weekly) to build tolerance and minimize gastrointestinal side effects.
- Titration: In clinical trials for these individual molecules, doses are gradually increased over several weeks based on individual tolerance.
- Storage: Reconstituted vials must be stored in a refrigerator (2°C to 8°C) to maintain stability.




Reviews
There are no reviews yet.